Inhibikase Therapeutics raises $50M via ATM sale

Rhea-AI Filing Summary

Inhibikase Therapeutics, Inc. disclosed that it sold 25,000,000 shares of common stock to RA Capital Management through its at-the-market facility, generating gross proceeds of $50 million under an existing shelf registration statement on Form S-3 and related ATM prospectus supplement.

The company expects this additional capital, together with existing cash reserves, to support operations through topline data readout in Part B of its ongoing global Phase 3 IMPROVE-PAH trial of IKT-001 for Pulmonary Arterial Hypertension, subject to the full exercise of outstanding Series A and B Warrants.

Inhibikase is a clinical-stage pharmaceutical company developing IKT-001, a prodrug of imatinib, for Pulmonary Arterial Hypertension, a progressive, life-threatening disease that affects approximately 50,000 Americans, with its single pivotal Phase 3 IMPROVE-PAH study actively enrolling at about 180 sites worldwide.

Filing Explained

The completed equity sale expands the share base and brings gross financing proceeds alongside $49.6 million of cash and $120.8 million of short-term investments.

The July 14 Form 8-K records a completed sale of $50 million gross through the ATM facility, including 25,000,000 common shares; as additional shares, the transaction increases the share base and reduces existing holders’ percentage ownership.

The ATM is the mechanism used for the sale, while the Form S-3 supplied registration capacity and the prospectus supplement supplied the takedown terms; this filing reports an actual completed sale rather than merely available shelf capacity.

At March 31, 2026, cash and equivalents were $49,573,510, alongside $120,795,235 of short-term investments.

The company’s stated ability to support operations through the Part B topline readout remains conditional on full exercise of the outstanding Series A and B Warrants, as disclosed in the July 14 press release.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Shares Sold: 25,000,000 shares Gross Proceeds: $50 million PAH Patients in U.S.: approximately 50,000 +4 more

7 metrics

Shares Sold 25,000,000 shares Common stock sold to RA Capital Management through at-the-market facility

Gross Proceeds $50 million Gross proceeds from the at-the-market sale of common stock

PAH Patients in U.S. approximately 50,000 Estimated number of Americans affected by Pulmonary Arterial Hypertension

Phase 3 Trial Sites approximately 180 sites Global sites participating in the IMPROVE-PAH pivotal Phase 3 study

S-3 Effectiveness Date June 27, 2025 Date the SEC declared the Form S-3 shelf registration effective

ATM Prospectus Supplement Date December 19, 2025 Filing date of the ATM offering prospectus supplement under Rule 424(b)

Imatinib Initial U.S. Approval Year 2001 Year imatinib was first approved in the United States

Key Terms

at-the-market facility, shelf registration statement, prospectus supplement, Pulmonary Arterial Hypertension, +1 more

5 terms

at-the-market facility financial

"sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the-market"

An at-the-market facility is a standing arrangement that lets a publicly traded company sell new shares directly into the open market at whatever the current market price is, typically through an investment bank acting as a sales agent. For investors it matters because it provides the company with a flexible way to raise cash without a large, one-time share offering; however, selling additional shares can dilute existing ownership and, by increasing supply, may pressure the stock price like adding more tickets to a limited-seat event.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3 (File No. 333-288213)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"and a prospectus supplement relating to the ATM offering filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Pulmonary Arterial Hypertension medical

"developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”)"

Pulmonary arterial hypertension is a progressive medical condition in which the arteries that carry blood from the heart to the lungs become narrowed or stiff, causing high pressure in the lung circulation and extra strain on the heart — like a pump working against clogged pipes. For investors, it matters because the condition defines the need, market size, clinical trial design, regulatory hurdles and potential revenue or risk for companies developing drugs, devices or diagnostics to treat or manage it.

Phase 3 IMPROVE-PAH clinical study medical

"Part B of the Company’s ongoing global Phase 3 IMPROVE-PAH clinical study"

FAQ

What financing did Inhibikase Therapeutics (IKT) announce on July 14, 2026?

Inhibikase announced it sold 25,000,000 shares of common stock to RA Capital Management, raising $50 million through its at-the-market facility. The shares were issued under an effective Form S-3 shelf registration and an ATM prospectus supplement filed in December 2025.

How does the $50 million capital raise impact Inhibikase (IKT)'s cash runway?

Inhibikase expects the $50 million raise, combined with existing cash, to fund operations through topline data from Part B of its Phase 3 IMPROVE-PAH trial. This expectation is subject to the full exercise of the company’s outstanding Series A and B Warrants.

What is IKT-001, the lead drug candidate for Inhibikase (IKT)?

IKT-001 is described as a prodrug of imatinib mesylate being developed to treat Pulmonary Arterial Hypertension. Imatinib was first approved in the United States in 2001 for cancers and blood disorders and has a long-established clinical safety profile.

What is the IMPROVE-PAH Phase 3 study mentioned by Inhibikase (IKT)?

IMPROVE-PAH is Inhibikase’s single pivotal Phase 3 clinical study of IKT-001 in Pulmonary Arterial Hypertension. The trial is being conducted at approximately 180 sites worldwide and is actively enrolling patients to evaluate pulmonary vascular resistance and outcome variables.

How prevalent is Pulmonary Arterial Hypertension according to Inhibikase (IKT)?

Inhibikase states that Pulmonary Arterial Hypertension is a progressive, life-threatening disease affecting approximately 50,000 Americans. The condition involves pulmonary vascular remodeling and elevated pulmonary vascular resistance, underscoring the potential need for disease-modifying therapies such as IKT-001.

Under which regulatory framework did Inhibikase (IKT) sell the new shares?

The shares were sold under a Form S-3 shelf registration declared effective on June 27, 2025, and an ATM prospectus supplement filed on December 19, 2025. The sale used the company’s at-the-market facility to issue common stock to RA Capital Management.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/14/2026 - 08:11 AM Accepted by SEC EDGAR 07/14/2026 - 08:11 AM Learn about SEC filing dates

false 0001750149 0001750149 2026-07-14 2026-07-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 14, 2026

INHIBIKASE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39676		26-3407249
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1000 N. West Street, Suite 1200 Wilmington, DE		19801
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (302) 295-3800

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IKT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On July 14, 2026, Inhibikase Therapeutics, Inc. (the “Company”) issued a press release relating to sales made by the Company under its at-the-market facility. The Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Number		Description
99.1		Press Release issued by Inhibikase Therapeutics, Inc., dated July 14, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 14, 2026				INHIBIKASE THERAPEUTICS, INC.
				By:		/s/ Mark Iwicki
						Mark Iwicki
						Chief Executive Officer

Exhibit 99.1

Inhibikase Therapeutics Announces Sale

of $50 Million of Shares Through its At-the-Market (ATM) Facility

WILMINGTON, Del., July 14, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that it has sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the-market (“ATM”) facility for gross proceeds of $50 million.

The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in Part B of the Company’s ongoing global Phase 3 IMPROVE-PAH clinical study, subject to the full exercise of the outstanding Series A and B Warrants.

The shares of common stock described above were sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-288213), which was declared effective by the SEC on June 27, 2025, and a prospectus supplement relating to the ATM offering filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on December 19, 2025 (the “ATM prospectus supplement”). Electronic copies of the ATM prospectus supplement and the accompanying prospectus are available on the SEC’s website at http://www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Inhibikase

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s expected cash runway. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:

Investor Relations:

Michael Moyer

LifeSci Advisors

mmoyer@lifesciadvisors.com

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 7.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB